| Title |
The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, August 2006
|
| DOI | 10.1007/s00432-006-0132-6 |
| Pubmed ID | |
| Authors |
William A. See, Chris J. Tyrrell, on behalf of the CASODEX™ Early Prostate Cancer Trialists’ Group |
| Abstract |
Castration therapy adjuvant to radiotherapy can significantly improve overall survival compared with radiotherapy alone in patients with locally advanced prostate cancer. Although many of the adverse effects of castration therapy are manageable, they can have a detrimental effect on quality of life. Here we evaluate the efficacy and tolerability of the non-castration-based therapy bicalutamide ('Casodex') 150 mg adjuvant to radiotherapy in patients with T1-4, M0, any n prostate cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 2% |
| Unknown | 46 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 15% |
| Researcher | 6 | 13% |
| Other | 5 | 11% |
| Student > Postgraduate | 4 | 9% |
| Student > Master | 4 | 9% |
| Other | 11 | 23% |
| Unknown | 10 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 53% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Chemistry | 2 | 4% |
| Immunology and Microbiology | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 14 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2021.
All research outputs
#4,415,538
of 23,815,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#209
of 2,632 outputs
Outputs of similar age
#10,956
of 66,797 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#1
of 10 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,632 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 66,797 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them